UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: NAV, Returns and Maturity Status Compared
- July 21, 2026
- Posted by: Kunal Singla
- Category: News
UTI Long Term Advantage Fund Series III NAV Rs 23.2926, 16.62% CAGR since 2016. Sundaram Long Term Tax Advantage Fu matured, final NAV Rs 31.7125, lifetime CAGR 11.96%.
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct compares two schemes that have both already matured. UTI Long Term Advantage Fund Series III closed at a final NAV of Rs 23.2926 in 2021, while the comparison fund closed at Rs 31.7125 in 2025, and neither is available for fresh investment today.
That difference shapes what UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct means for you. If you hold units in either scheme, the lock in period has ended, so the choice is between redeeming now, holding until maturity, or reallocating toward an open ended ELSS fund that accepts fresh money and runs a SIP.
Click Here – Get Free Investment Predictions
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: Quick Comparison Table
The table below sets out UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct on structure, NAV and verified returns computed from official AMFI NAV history.
| Parameter | UTI Long Term Advantage Fund Series III | Sundaram Long Term Tax Advantage Fund Series I Direct Plan |
|---|---|---|
| Fund house | UTI Mutual Fund | Sundaram Mutual Fund |
| Category | Close ended ELSS | Close ended ELSS |
| Units allotted | 2016 | 2015 |
| Current status | Matured in 2021 | Matured in 2025 |
| Latest / final NAV | Rs 23.2926 | Rs 31.7125 |
| CAGR since launch | 16.62% per year | 11.96% per year |
| Total return since launch | About 132.4% | About 209.0% |
| Lock in | 3 years (already over) | 3 years (already over) |
| Fresh investment allowed | No, NFO only scheme | No, NFO only scheme |
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: NAV and Live Performance
The UTI Long Term Advantage Fund Series III side of UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct has compounded investor money at 16.62 percent per year since units were allotted in 2016, a total gain of about 132.4 percent to date. Based on AMFI NAV history, it has also delivered a 3 year CAGR of 18.67 percent and a 5 year CAGR of 15.21 percent.
The comparison fund in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct, Sundaram Long Term Tax Advantage Fund Series I Direct Plan, has compounded at 11.96 percent per year since 2015, a total return of about 209.0 percent locked in at its final NAV.
Use the Univest Screener to Compare Live Fund and Stock Data
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: Maturity and Investment Status
Structurally, UTI Long Term Advantage Fund Series III is a close ended ELSS. It accepted money only during its 2016 new fund offer, gave investors Section 80C tax benefits, and imposed a three year lock in. Since that lock in ended, unitholders have been free to redeem on any business day at NAV, and the scheme has since completed its full life cycle and matured.
The comparison fund in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct followed the same structure. It has already completed its full life cycle, with outstanding units compulsorily redeemed at the prevailing NAV of Rs 31.7125 in 2025.
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: Which Fund Performed Better
On pure lifetime CAGR, UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct tilts toward UTI Long Term Advantage Fund Series III, which has compounded at 16.62 percent per year versus 11.96 percent per year for the other scheme. Entry and exit timing plays a real role here since ELSS NFOs launched in different market cycles naturally show different lifetime returns.
Total wealth created can tell a different story than annualised CAGR in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct. A scheme that has stayed invested longer compounds a larger absolute gain even at a lower annual rate, while a matured scheme locks in its return the moment it closes and forces the investor to find a new home for that money, which carries its own reinvestment risk.
The honest verdict from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct is that both schemes broadly did their job as Section 80C tax savers. Each one delivered a healthy multi year return well ahead of inflation. The bigger lesson from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct sits in the close ended structure itself, not in which fund edged ahead.
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct: Key Takeaways for Tax Saving Investors
Close ended ELSS schemes, as UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct shows, are largely a discontinued category today. You cannot add money after the NFO, you cannot run a SIP, and your exit at maturity may or may not land in a favourable market. Open ended ELSS funds solve all three problems while offering the same Section 80C benefit and the same three year lock in per instalment.
If you still hold either fund from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct, review it the way you would any equity fund. The lock in is over on both sides, so the choice between redeeming now and holding until maturity should rest on your goals, your tax situation on gains, and whether the money has a better destination. A SEBI registered investment adviser can help you weigh that call against your full portfolio.
Many investors researching UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct also want to know how the lock in and tax treatment compare before deciding where to hold their money.
For a reader evaluating UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct, the NAV figures above are the fastest way to see which scheme has compounded faster to date.
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct is a useful reference point whenever either scheme comes up in a broader ELSS portfolio review.
Anyone tracking UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct should note that neither scheme is open for new lump sum or SIP investment today.
The comparison in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct is most useful for existing unitholders deciding whether to redeem, hold, or reinvest elsewhere.
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct also matters for investors comparing Section 80C options across different fund houses before their next tax filing.
Download the Univest iOS App or Univest Android App to track funds, stocks and SEBI registered research in one place.
Conclusion
UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct ultimately does not favour one fund by a wide margin. UTI Long Term Advantage Fund Series III shows a verified CAGR of 16.62 percent since 2016, while the comparison fund has compounded at 11.96 percent since 2015. Neither side of UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct accepts fresh money today, so for new tax saving investment in FY 2026-27, an open ended ELSS with a consistent track record is the practical route. Historically, disciplined ELSS investing has rewarded patience, but always consult a SEBI registered adviser before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct
In UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct, which fund performed better?
Ans. On lifetime CAGR, UTI Long Term Advantage Fund Series III finished ahead at about 16.62 percent per year, versus 11.96 percent per year for the other scheme in this comparison. Total wealth created can still favour the scheme that has stayed invested longer, even at a lower annual rate.
What is the latest NAV of UTI Long Term Advantage Fund Series III in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct?
Ans. The final NAV of UTI Long Term Advantage Fund Series III is Rs 23.2926, per official AMFI data, declared in 2021 at maturity.
Is the comparison fund in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct still active?
Ans. No, it has already matured. Its final declared NAV was Rs 31.7125, declared in 2025, after which the scheme stopped publishing NAVs and proceeds were paid out to unitholders.
Can I invest in either fund from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct today?
Ans. No fresh investment is possible in either scheme covered in UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct. Both are close ended ELSS schemes that accepted subscriptions only during their respective new fund offers, and neither is accepting or holding new investor money now.
What type of fund is UTI Long Term Advantage Fund Series III?
Ans. UTI Long Term Advantage Fund Series III is a close ended equity linked savings scheme, or ELSS, from UTI Mutual Fund. Investments made during its NFO qualified for Section 80C tax deduction and carried a three year lock in period.
What returns has UTI Long Term Advantage Fund Series III delivered?
Ans. UTI Long Term Advantage Fund Series III has compounded at roughly 16.62 percent per year since its 2016 launch, a total gain of about 132.4 percent, with a 3 year CAGR of 18.67 percent per the latest AMFI NAV history.
What happened to investors in the UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct comparison at maturity?
Ans. At maturity, outstanding units were compulsorily redeemed at the prevailing NAV and the proceeds were paid to unitholders. This is the standard process for every close ended ELSS scheme once its tenure ends.
What is the key takeaway from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct?
Ans. The key takeaway from UTI Long Term Advantage Fund Series III vs Sundaram Series I Direct is that close ended ELSS schemes cannot take fresh money after their NFO, so investors comparing them today should treat this as a reference case rather than a live investment choice. An open ended ELSS fund with a consistent long term record is the practical route for new tax saving investment.
